Merck, TRACRRNAMOD-5NMOL, SygRNA™ Cas9 Synthetic Modified tracrRNA

General description
The SygRNA modified synthetic RNA system recruits WT SpCas9, eSpCas9, dCas9, or Cas9D10A to specific genomic targets. 2′ O-methyl and phosphothioate modifications have been incorporated to enhance the stability and performance of the synthetic RNA. The modified tracrRNA (trans-activating crRNA) binds to a crRNA (CRISPR RNA) and the resulting crRNA-tracrRNA complex guides SpCas9 and SpCas9 variant proteins to crRNA-specified sites in the genome. SygRNA modified synthetic tracrRNA and crRNAs are optimized for use with a variety of Cas9 expressing cell lines, Cas9 proteins, or Cas9 mRNAs and are compatible with a delivery methods such as microinjection, lipofection, and electroporation.
Application
Functional Genomics/Target Validation/Transgenics

Creation of gene knockouts in multiple cell lines
Complete knockout of genes not amenable to RNAi
Creation of knock-in cell lines with promoters, fusion tags, or reporters integrated into endogenous genes
Generation of transgenic animals via embryo microinjection or electroporation

Features and Benefits
HPLC-purified SygRNA modified tracrRNA oligo is optimized for use with a target-specific crRNA or modified crRNA and a source of SpCas9 protein for genome editing applications.
Preparation Note
Resuspend SygRNA modified tracrRNA oligo in a RNAase-free Tris-containing buffer with a pH 8.0 or less.
Other Notes
The SygRNA Cas9 tracrRNA oligo is used in conjunction with a target-specific crRNA and a source of Cas9 protein to form active RNP complexes.

Visit SigmaAldrich.com/CRISPRessentials to to review available Cas9 sources.

Order crRNAs at SigmaAldrich.com/CRISPR
Legal Information
CRISPR Use License Agreement
SygRNA is a trademark of Sigma-Aldrich Co. LLC